Skip to main content

Investors

Il Gruppo Ulisse Biomed è un gruppo biotech integrato con tecnologie proprietarie, che sviluppa soluzioni diagnostiche, con un focus su salute pubblica, diagnostica distribuita e innovazione molecolare.

Investors

Il Gruppo Ulisse Biomed è un gruppo biotech intyegrato con tecnologie proprietarie, che sviluppa soluzioni diagnostiche, con un focus su salute pubblica, diagnostica distribuita e innovazione molecolare.

31 Dicembre, 2020

Notizie e aggiornamenti

Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection


Hyris CE-IVD marked test for COVID human diagnostic "bKIT Virus Finder COVID-19" is at the core of the signature Article "Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection", from the Department of Laboratory Medicine of the National Institute for The Study and Treatment of Cancer IRCCS "Fondazione G Pascale" (IRCCS Pascale), of Naples (Italy)

The easy access to a quick diagnosis of coronavirus disease 2019 (COVID-19) is a key point to improve the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to contain its spread. Up to now, laboratory real-time PCR is the standard of care, but requires a fully equipped laboratory and significant infrastructure. Consequently, new diagnostic tools are required.

Professor Leonardo Miscio and his colleagues evaluated the diagnostic accuracy of Hyris point-of-care rapid test "bKIT Virus Finder COVID-19", both by a retrospective and a prospective analysis.

Results obtained are entirely comparable to the standard laboratory-based real-time PCR methods for all the analyzed samples, with a much faster result and no need for an equipped facility.

This authoritative Article furtherly strengthens the Hyris System's relevance for human diagnostic, now empowered via the CE-IVD marked 'bKIT Virus Finder COVID-19', as it represents indeed a promising tool to improve the health surveillance and to increase the overall capacity of SARS-CoV-2 testing.

Hyris System confirms to be a key asset in the global fight against the last Coronavirus.

Read the full article HERE